Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - alpha-cypermethrin - suspension concentrate - alpha-cypermethrin pyrethroid active 300.0 g/l - insecticide

Australia - English - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 1000 mg - diluent, not applicable - excipient ingredients: - prolastin-c is an alpha-1-proteinase inhibitor (human, alpha1-pi) indicated to increase serum alpha1-pi levels in adults with congenital deficiency of alpha-1 antitrypsin and with clinically significant emphysema (fev1 less than 80%). the data for clinical efficacy of prolastin-c is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials. clinical trials have only included patients who were not smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

bomax pty ltd - evening primrose oil, quantity: 1 g - capsule, soft - excipient ingredients: d-alpha-tocopherol; soya oil; gelatin; glycerol; purified water - well - aids or assists in maintenance or improvement of general well-being. skin1 - for the symptomatic relief of eczema skin3 - for the symptomatic relief of dermatitis skin9 - may assist in the management of eczema skin11 - may assist in the management of dermatitis mens4 - relief of premenstrual breast pain mens5 - for the symptomatic relief of pre-menstrual syndrome) mens9 - may assist in the management of pre-menstrual syndrome arth1 - aids in the temporary relief of the pain of arthritis or temporary relief of arthritic pain rheum4 - may assist in the management of rheumatism rheum - temporary relief of rheumatism or temporary relief of rheumatic pain arth4 - may help increase joint mobility associated with arthritis rheum2 - symptomatic relief of rheumatism * evening primrose oil is a valuable source of the omega 6 fatty acid gamma-linolenic acid. * supports the healing and repair of the skin. * may assist in the relief of flaking, scaling and itching of the skin. * relief of pre-menstrual symptoms/syndrome. * assists in the maintenance of a healthy cardiovascular system

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - evening primrose oil, quantity: 1000 mg (equivalent: gamma-linolenic acid, qty 100 mg) - capsule, soft - excipient ingredients: purified water; d-alpha-tocopherol; gelatin; glycerol - maintain/support general health and wellbeing ; maintain/support female healthy hormonal balance ; decrease/reduce/relieve symptoms of premenstrual tension ; decrease/reduce/relieve symptoms of mild eczema/dermatitis ; maintain/support skin health

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate, quantity: 575 mg (equivalent: amoxicillin, qty 500 mg) - capsule, hard - excipient ingredients: sodium starch glycollate; purified talc; sodium lauryl sulfate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; iron oxide yellow; gelatin - treatment of the following infections due to susceptible strains of sensitive organisms. note. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure staphylococcus, non-penicillinase producing; streptococcus; e. coli (see microbiology). respiratory (acute and chronic) h. influenzae; streptococcus; s. pneumoniae; staphylococcus, non-penicillinase producing; e. coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic) p. mirabilis; s. faecalis; e. coli (see microbiology). gonorrhoea n. gonorrhoea (non-penicillinase producing). prophylaxis of endocarditis amoxycillin may be used for the prophylaxis of bacterial en

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate, quantity: 288 mg (equivalent: amoxicillin, qty 250 mg) - capsule, hard - excipient ingredients: purified talc; sodium starch glycollate; microcrystalline cellulose; sodium lauryl sulfate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; iron oxide yellow; gelatin - treatment of the following infections due to susceptible strains of sensitive organisms. note. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure staphylococcus, non-penicillinase producing; streptococcus; e. coli (see microbiology). respiratory (acute and chronic) h. influenzae; streptococcus; s. pneumoniae; staphylococcus, non-penicillinase producing; e. coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic) p. mirabilis; s. faecalis; e. coli (see microbiology). gonorrhoea n. gonorrhoea (non-penicillinase producing). prophylaxis of endocarditis amoxycillin may be used for the prophylaxis of bacterial en

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydralazine hydrochloride, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; disodium edetate; purified talc - this product accepted for registration as 'currently supplied' at the time of commencement of the act. variation to pregnancy statement in product information were approved as specified in the letter of 13 august 1992 from dr bijoy varma. indicated for the treatment of drug resistant, moderate to severe, hypertension. this drug is not a first line antihypertensive drug and is better used in combination with other therapy such as a sympatholytic agent and a diuretic. indications as at 28 november 2001 : hypertension (drug resistant, moderate to severe): as supplementary medication for use together with other antihypertensives such as "beta"-blockers and diuretics; the complementary mechanisms of action of such combined therapy enable the drugs to exert their antihypertensive effects at low doses; in addition, unwanted accompanying effects of the individual substances are either partially offset or even cancelled out.

United States - English - NLM (National Library of Medicine)

grifols usa, llc - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1000 mg in 20 ml - prolastin-c is an alpha1 -proteinase inhibitor (human) (alpha1 -pi) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1 -pi (alpha1 -antitrypsin deficiency). prolastin-c increases antigenic and functional (anti-neutrophil elastase capacity, anec) serum levels and antigenic lung epithelial lining fluid levels of alpha1 -pi. limitations of use - the effect of augmentation therapy with any alpha1 -pi, including prolastin-c, on pulmonary exacerbations and on the progression of emphysema in alpha1 -pi deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. - clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with prolastin-c are not available. - prolastin-c is not indicated as therapy for lung disease in patients in whom severe alpha1 -pi deficiency has not been established. prolastin-c is contraindicated in: - iga deficient patients w

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydralazine hydrochloride, quantity: 50 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate; colloidal anhydrous silica; purified talc; disodium edetate; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; sunset yellow fcf; iron oxide yellow; macrogol 4000; erythrosine - this product accepted for registration as 'currently supplied' at the time of commencement of the act. amended product information (variation to pregnancy statement) was approved as specified in the letter of 13 august 92 from dr bijoy varma. indications as at 28 november 2001 : hypertension (drug resistant, moderate to severe): as supplementary medication for use together with other antihypertensives such as "beta"-blockers and diuretics; the complementary mechanisms of action of such combined therapy enable the drugs to exert their antihypertensive effects at low doses; in addition, unwanted accompanying effects of the individual substances are either partially offset or even cancelled out.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate -